Miso,It was always a Cooked story – a great settlement, a change...

Miso,
It was always a Cooked story – a great settlement, a change in CEO, better relationship, lots of bulls.

Immediately upon settlement, GSK started selling Relenza call options. And today’s results reveal a lot more.

Relenza sales fell 80% contrast to GSK Flu prepandemic vaccine falling 55%. It proved GSK still had to be dragged out of bed by the scientific community to supply Relenza,
One of Miso’s post on the shortage of Relenza in pharmacies is truly reflected in the GSK results! Here’s Miso’s post:
http://www.hotcopper.com.au/post_threadview.asp?fid=1&tid=819992#3693421

In so far as seasonal flu is concern GSK Flu vaccines sales increased by 11%. It is funny to see Peter Cook blamed poor seasonal flu season when all of us know Relenza sales to the seasonal flu market was and still is close to zilch.

At 13 million GBP (29.3 million AUD) the royalty at 7% is approximately 2 million AUD. For half of this financial year, the royalty added to the $1.9 m last quarter is a miserable $3.9m compared to the 20 to 30 million predicted by the euphoric brokers reports on BTA website to give a “cash neutral year”. Very soon the half year results will reveal the truth.

Let's hope for the boys who cried woolves too many times, the scientific community can remove the Tamiflu blindfold from their governments' eyes and more orders for Relenza materialises.




.